[Skip to the guide](#reading) [Find your next question. Read the path.](/#path) [Who Prescribes Peptides](/) [Begin](/starting-point) [Visits](/visit-route) [Costs](/cost-map) Chapters Find your question [What the word peptide means](/starting-point) [Who can write a prescription](/prescriber-map) [Where to begin looking](/care-route) Check access to care [Check the prescriber](/license-map) [Where the visit takes place](/state-route) [Online or in person](/visit-route) Name the medicine [Name the medicine first](/medicine-map) [What compounding changes](/compounding-route) [How to read a health claim](/evidence-map) Prepare for the visit [Questions for the first visit](/question-map) [What an assessment may involve](/test-route) [What the whole plan may cost](/cost-map) Check the arrangements [Ask your plan about coverage](/coverage-route) [Check who fills the prescription](/pharmacy-map) [Reasons to pause](/red-flag-route) Plan the follow-up [Problems that need a response](/risk-map) [Keep a route back to care](/follow-up-route) [Return to the original source](/source-route) From first question to an actual prescriber, in steps. Prescribes for nobody. [Home](/) /How to read a health claim Step nine · Name the medicine # How to read a health claim Follow a claim back to the source and ask what the evidence can actually answer. This is a guide. Nobody is seen, prescribed for, or booked through these pages. [1. Begin](/starting-point) [2. Access](/license-map) [3. Medicine](/medicine-map) [4. Questions](/question-map) [5. Arrangements](/coverage-route) [6. Follow-up](/risk-map) ## In this part of the path [Name the medicine first](/medicine-map) [What compounding changes](/compounding-route) [How to read a health claim](/evidence-map) Move at your own pace. These steps organize questions, not treatment. ## Read past a confident claim ![Plain books on a green linen reading surface, with every page angled beyond readable detail](/carepath/reading-the-claim.483fe093.webp) A confident sentence can sound complete while leaving out the medicine, the people studied, or the question the study asked. Start by copying the claim into your own notes. Then ask what original document supports it. Keep the claim beside the source so you can compare the words rather than rely on a summary of a summary. Ask whether the document concerns the exact product being proposed. Is it about the same form and the same use? Does it describe a result, a plan for research, or someone's interpretation? You do not have to judge every research method to notice when those questions have not been answered. ## Keep the source tied to the claim FDA approvals in the September 2026 record belonged to particular products and uses, including semaglutide and tirzepatide medicines. The federal agency that reviews drugs uses the abbreviation FDA for Food and Drug Administration. Compounded preparations had no FDA approval, and FDA did not check their safety, quality, or whether they worked before sale. If a claim shifts between those categories, ask for the difference to be made clear. As of September 2026, FDA described assertions that compounded drugs were clinically proven to match approved-drug results as false or misleading. Ask the professional to explain the evidence for the proposed preparation rather than treating a familiar ingredient name as the full answer. ### Ask what the source leaves out Look for the limits described in the original document. What question did it not answer? What would the professional still need to assess about your circumstances? Ask them to explain both the reason for their proposal and the parts that remain uncertain. You can write down those limits alongside any expected benefit. Avoid turning a question about evidence into a test of how much technical language you know. Ask for an everyday explanation of the finding and its limits. If you cannot tell what the source studied after that explanation, ask to go through the title and conclusion together. ### A report is not proof of cause The term adverse event covers something unwanted that occurs while a person uses a medical product. FDA says the report alone cannot settle cause, medically confirm what happened, or establish the frequency of an event. This limit matters when a website uses a collection of reports to suggest a precise chance of harm. Ask what kind of evidence supports any statement about how often a problem occurs. Reaction rates for injectable medicines differ by product, so a rate for one peptide cannot describe all of them. Keep the product and the source attached to the number when discussing it with a professional. ### Read the status and the date together Under the September 2026 framework, an FDA advisory committee's vote was advice rather than a change to the compounding rules. An NDC directory entry also did not prove FDA approval in the September 2026 record. NDC stands for National Drug Code. Neither label is a shortcut around reading what the record actually says. Ask for the source's date and whether the person proposing care has checked for a later version. A dated statement may still be useful, but its date belongs with it. Next, [prepare questions for the first visit](/question-map) so the evidence discussion connects to the concern you brought rather than ending with a pile of links. ## Sources for this chapter Read each source with the limits described in this chapter. [Read the FDA semaglutide label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf) [FDA on making compounded medicines](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) [FDA on claims made about compounded drugs](https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs) [FDA limits on interpreting event reports](https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/fda-adverse-event-monitoring-system-aems-public-dashboard) [FDA ingredient-list framework](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act) [FDA on National Drug Code listings](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory) Continue the learning path ## Questions for the first visit [Read the next chapter](/question-map) [Return to the previous page](/compounding-route) [Who Prescribes Peptides](/) This reading guide follows the search for peptide care, with no clinical visits provided and no medicines sold. [Begin reading](/starting-point) [Original sources](/source-route) [Read as text](/evidence-map.md) © Who Prescribes Peptides